Clinical Trials Browser

INDUSTRY × Interventional × BCG Vaccine × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03711032 2025-12-22

MK-3475-676

Phase 3 Active not recruiting

1,397 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03528694 2025-11-25

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05037279 2025-02-20

EVER

Phase 3 Recruiting

540 enrolled

Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT02792192 2021-10-28

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Phase 1/2 Terminated

24 enrolled 18 charts

Genitourinary

Urinary Bladder Neoplasms

NCT00694915 2021-08-17

STCC

Phase 2 Completed

122 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02010203 2020-02-17

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Phase 1/2 Terminated

104 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT00003715 2015-12-03

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Phase 2 Terminated

425 enrolled

Dermatologic

Melanoma

NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00514072 2012-08-09

Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer

Phase 2 Unknown

54 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

CREST

MK-3475-676

POTOMAC

EVER

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

STCC

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer